Recursion Pharmaceuticals, Inc. RXRX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Recursion Pharmaceuticals, Inc. (RXRX) reported deferred tax assets and other non-current assets of $12.25M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets decreased by 17.1% year-over-year, from $14.78M to $12.25M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets has grown at a 81.4% compound annual growth rate (CAGR), from $650K to $12.75M.